1. Home
  2. AVBH vs TVRD Comparison

AVBH vs TVRD Comparison

Compare AVBH & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVBH
  • TVRD
  • Stock Information
  • Founded
  • AVBH 2003
  • TVRD 2017
  • Country
  • AVBH United States
  • TVRD United States
  • Employees
  • AVBH N/A
  • TVRD N/A
  • Industry
  • AVBH
  • TVRD Biotechnology: Pharmaceutical Preparations
  • Sector
  • AVBH
  • TVRD Health Care
  • Exchange
  • AVBH Nasdaq
  • TVRD Nasdaq
  • Market Cap
  • AVBH 282.1M
  • TVRD 246.5M
  • IPO Year
  • AVBH N/A
  • TVRD N/A
  • Fundamental
  • Price
  • AVBH $25.99
  • TVRD $4.87
  • Analyst Decision
  • AVBH Strong Buy
  • TVRD Buy
  • Analyst Count
  • AVBH 4
  • TVRD 7
  • Target Price
  • AVBH $28.38
  • TVRD $51.67
  • AVG Volume (30 Days)
  • AVBH 28.2K
  • TVRD 674.7K
  • Earning Date
  • AVBH 10-23-2025
  • TVRD 11-21-2025
  • Dividend Yield
  • AVBH N/A
  • TVRD N/A
  • EPS Growth
  • AVBH N/A
  • TVRD N/A
  • EPS
  • AVBH N/A
  • TVRD N/A
  • Revenue
  • AVBH $22,129,000.00
  • TVRD N/A
  • Revenue This Year
  • AVBH $21.53
  • TVRD N/A
  • Revenue Next Year
  • AVBH $17.90
  • TVRD N/A
  • P/E Ratio
  • AVBH N/A
  • TVRD N/A
  • Revenue Growth
  • AVBH N/A
  • TVRD N/A
  • 52 Week Low
  • AVBH $19.75
  • TVRD $4.48
  • 52 Week High
  • AVBH $26.59
  • TVRD $43.65
  • Technical
  • Relative Strength Index (RSI)
  • AVBH N/A
  • TVRD 19.82
  • Support Level
  • AVBH N/A
  • TVRD $5.65
  • Resistance Level
  • AVBH N/A
  • TVRD $7.23
  • Average True Range (ATR)
  • AVBH 0.00
  • TVRD 1.04
  • MACD
  • AVBH 0.00
  • TVRD -1.79
  • Stochastic Oscillator
  • AVBH 0.00
  • TVRD 1.00

About AVBH Avidbank Holdings Inc. Common stock

Avidbank Holdings Inc is a full-service commercial bank. It offers various services such as commercial and industrial lending, venture lending, structured finance, asset-based lending, sponsor finance, real estate construction, and commercial real estate lending.

About TVRD Tvardi Therapeutics Inc. Common Stock

Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.

Share on Social Networks: